J Alejandro Perez-Fidalgo
Overview
Explore the profile of J Alejandro Perez-Fidalgo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
784
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villacampa G, Eminowicz G, Navarro V, Carita L, Garcia-Illescas D, Oaknin A, et al.
Eur J Cancer
. 2025 Mar;
220:115329.
PMID: 40031426
Background: Several first-line therapeutic strategies have been evaluated alongside platinum-based chemotherapy in advanced or recurrent endometrial cancer (a/rEC). However, the optimal approach remains unclear. Methods: A systematic review was conducted...
2.
Gonzalez-Martin A, Rubio M, Heitz F, Christensen R, Colombo N, Van Gorp T, et al.
J Clin Oncol
. 2024 Sep;
42(36):4294-4304.
PMID: 39292975
Purpose: To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer. Methods: The multicenter placebo-controlled double-blind randomized phase III ENGOT-OV41/GEICO 69-O/ANITA trial (ClinicalTrials.gov...
3.
Alvarez C, Piazuelo M, Fleitas-Kanonnikoff T, Ruhl J, Perez-Fidalgo J, Camargo M
JAMA Netw Open
. 2024 Aug;
7(8):e2428828.
PMID: 39158910
Importance: The incidence of gastrointestinal stromal tumors (GISTs) increased after the implementation of GIST-specific histology coding in 2001, but updated data on trends and survival are lacking. Objective: To examine...
4.
Oaknin A, Gladieff L, Martinez-Garcia J, Villacampa G, Takekuma M, De Giorgi U, et al.
Lancet
. 2023 Dec;
403(10421):31-43.
PMID: 38048793
Background: The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10-GEICO 68-C-JGOG1084-GOG-3030), we aimed to evaluate the addition...
5.
Jhaveri K, Bellet M, Turner N, Loi S, Bardia A, Boni V, et al.
Clin Cancer Res
. 2023 Nov;
30(4):754-766.
PMID: 37921755
Purpose: Giredestrant is an investigational next-generation, oral, selective estrogen receptor antagonist and degrader for the treatment of estrogen receptor-positive (ER+) breast cancer. We present the primary analysis results of the...
6.
Samartzis E, Intidhar Labidi-Galy S, Moschetta M, Uccello M, Kalaitzopoulos D, Perez-Fidalgo J, et al.
Ann Transl Med
. 2021 Jan;
8(24):1712.
PMID: 33490224
Endometriosis is a benign gynecologic condition affecting up to one woman out of ten of reproductive age. It is defined by the presence of endometrial-like tissue in localizations outside of...
7.
Schmid P, Sablin M, Bergh J, Im S, Lu Y, Martinez N, et al.
Breast Cancer Res
. 2021 Jan;
23(1):8.
PMID: 33451345
Background: Xentuzumab-a humanised IgG1 monoclonal antibody-binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xentuzumab plus everolimus and exemestane...
8.
Perez-Fidalgo J, Grau F, Farinas L, Oaknin A
Crit Rev Oncol Hematol
. 2021 Jan;
158:103209.
PMID: 33388455
Despite optimal first-line treatment based on debulking surgery and platinum-paclitaxel chemotherapy, most of the patients with advanced ovarian cancer (AOC) will eventually relapse. Over the last decades, different strategies have...
9.
Garcia-Martinez E, Perez-Fidalgo J
EJC Suppl
. 2020 Nov;
15:87-95.
PMID: 33240447
Ovarian cancer is the leading cause of death for gynaecological cancer, and new therapies are urgently awaited. Although the presence of tumour-infiltrating lymphocytes has been confirmed to be associated to...
10.
Perez-Fidalgo J
EJC Suppl
. 2020 Nov;
15:73-76.
PMID: 33240445
Cancer is characterised by uncontrolled proliferation and prolonged cell survival. In some cases, tumour formation is the result from aberrant activity of various cell-cycle regulators leading to chromosome instability or...